Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoGenomics Signs Strategic Supply Agreement With Abbott
NeoGenomics has entered into a strategic supply agreement with Abbott. The deal provides for Abbott to supply materials for NeoGenomics to develop its own FISH (fluorescence in situ
NeoGenomics has entered into a strategic supply agreement with Abbott. The deal provides for Abbott to supply materials for NeoGenomics to develop its own FISH (fluorescence in situ
Teva has entered into an agreement with Ortho-McNeil-Janssen to settle the patent infringement lawsuit in the US District Court for the District of New Jersey. It is related
UCB has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA), for Keppra. Reportedly, the positive opinion
The EU’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Roche’s MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic
Merck & Co. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending expanded marketing authorisation for ISENTRESS (raltegravir) in combination with
Ambrilia has reported the termination of the phase III clinical Study 303. The move is in line with the company’s ongoing measures to effectively reduce costs. Reportedly, study
Kinetic Concepts has reported that the US Patent and Trademark Office (USPTO) has issued office actions confirming the validity of three separate patents licensed to KCI by Wake
NeurogesX has reported the preliminary results of a short-term clinical study (Study C123) of Qutenza in patients with postherpetic neuralgia (PHN), following pretreatment with an FDA-approved topical anesthetic.
Schering-Plough’s investigational drug SAPHRIS (asenapine) met the primary endpoint over one year of treatment in an extension study in patients with predominant, persistent negative symptoms of schizophrenia. Negative
Aurobindo has received the final approval for Zidovudine Tablets 60mg (NDA 22-294) and tentative approval for Lamivudine & Zidovudine Tablets 30mg/60mg(NDA 22-296) from the US Food and Drug